• Increase
  • Decrease
  • Normal

Current Size: 100%

Ed Forum 2017

News

March 19, 2015

More good news on the world-wide expansion of support services for WM patients comes from Downunder Australia.

Last update: 2015-03-19 09:54

March 5, 2015

The IWMF’s newest International Affiliate, WM-España, is based in Navarra, Spain under the leadership of Miguel Angel Berrueta.

Last update: 2015-03-05 10:42

March 3, 2015

The Amyloidosis Foundation is offering a free, one hour webinar on March 16th from 4:00-5:00 EST. This seminar will be conducted by Dr. Morie Gertz of the Mayo Clinic.

Last update: 2015-03-03 09:47

February 26, 2015

From February 27 to March 1, the Lymphoma Coalition (LC), an international network of lymphoma patient groups that includes the IWMF, will be running an ad in USA Today.

Last update: 2015-02-26 11:24

February 25, 2015

IWMF President and WM patient Carl Harrington has written an article entitled “What To Do When Diagnosed With a Rare Cancer,"

Last update: 2015-03-18 15:17

February 16, 2015

The IWMF’s newest International Affiliate, Macroglobulinemia De Waldenstrom Argentina, is based in Buenos Aires, Argentina, under the leadership of Graciela Silvia Molina, MD.

Last update: 2015-02-17 08:37

February 9, 2015

To provide the latest news on advances in WM research and treatments, and up-to-the minute information on our services to members, the IWMF will use both Facebook and Twitter.

Last update: 2015-02-09 19:52

February 4, 2015

Oncology Nursing News magazine interviewed Carl Harrington, president of the IWMF, about the US FDA's decision to approve imbruvica (ibrutinib).

Last update: 2015-02-06 19:30

February 3, 2015

Cure magazine (http://www.curetoday.com) interviewed Carl Harrington, president of the IWMF, to properly present the impact that the US FDA's decision to approve imbruvica (ibrutinib) specifically for WM has on WM patients.

Last update: 2015-02-05 15:03

January 29, 2015

In a history-making moment for WM patients, the IWMF is pleased to announce that Imbruvica (ibrutinib) has just received FDA approval specifically for the treatment of WM, thus becoming the first drug therapy to achieve this designation.

Last update: 2015-01-29 18:25

Pages